Subscribe
Magazine
Past Issues
Surveys
Industry Statistics
About Us
Members Only
Best Places to Work
General Interest
Exploration & Development
Drilling & Production
Refining & Processing
Pipelines & Transportation
LNG
Energy Transition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Lexaria Bioscience Corp WT
(NQ:
LEXXW
)
1.500
UNCHANGED
Streaming Delayed Price
Updated: 3:54 PM EDT, Sep 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexaria Bioscience Corp WT
< Previous
1
2
3
4
5
6
Next >
Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1
March 05, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Weight-Loss Results in Animal Study, Begins Eight-Week Follow-Up Study
March 04, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
7% Weight Loss in Animals Supports Lexaria’s Next 8-week Animal Study
March 04, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Commence HYPER-H23-1 Clinical Trial
March 01, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program
January 16, 2024
Via
ACCESSWIRE
Lexaria's Groundbreaking Research into DehydraTECH-CBD Published in International Journal of Molecular Science
June 22, 2023
Via
ACCESSWIRE
Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial
March 01, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Closing of $3.6M Registered Direct Offering
February 20, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
February 16, 2024
Via
ACCESSWIRE
Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
February 15, 2024
Via
ACCESSWIRE
Lexaria's Submits Investigational New Drug Application
January 30, 2024
Via
ACCESSWIRE
Lexaria Releases Annual Letter from the CEO
January 24, 2024
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Extensive GLP-1 Study Program
January 16, 2024
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria's Investigational New Drug Application Filing Update
December 07, 2023
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Tech Lowers Blood Glucose More Effectively than Branded GLP-1 drug Semaglutide Alone, Study Shows
November 28, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria's Technology Lowers Blood Glucose More Effectively than Rybelsus(R)-Branded GLP-1 drug Semaglutide Alone in Human Pilot Study
November 28, 2023
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Shown to Improve Oral Performance of GLP-1 Drug in Human Pilot Study
November 27, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn
October 13, 2023
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Portfolio Expansion to 37 Granted Patents
October 12, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria Granted Two New Patents in Canada
October 12, 2023
Via
ACCESSWIRE
Lexaria Announces Pricing of $1.6 Million Registered Direct Offering
September 29, 2023
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces New Studies to Examine DehydraTECH(TM)-Powered GLP-1 Drugs
September 21, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD
September 21, 2023
Via
ACCESSWIRE
Lexaria Provides Update on Investigational New Drug Application Progress
August 30, 2023
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Results from Human Oral Nicotine Study Evaluating DehydraTECH(TM)-Nicotine
August 09, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria's DehydraTECH-Nicotine Faster than ZYN and on!
August 09, 2023
Via
ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Designing Human Clinical Study of DehydraTECH-CBD for Weight Loss, Diabetes Control
August 02, 2023
Via
CannabisNewsWire
Topics
Intellectual Property
Exposures
Intellectual Property
Lexaria’s Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD
August 02, 2023
Via
ACCESSWIRE
Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study
July 28, 2023
Via
ACCESSWIRE
Lexaria Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products
July 19, 2023
Via
ACCESSWIRE
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.